NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NovoCure Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$14.89+0.82 (+5.83%)
Close on Oct 19, 2026
- Market cap
- $1.73B
- P/E (TTM)
- –
- Dividend yield
- –
NovoCure Ltd revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $397.13M | $388.43M | $385.63M | $391.23M | $392.96M | $394.41M | $391.80M | $375.91M | $363.81M | $355.06M | $349.74M | $357.05M | 56.8% | +1.1% |
| International markets - Total | $281.08M | $266.36M | $250.28M | $234.26M | $221.39M | $210.23M | $196.03M | $182.02M | $164.21M | $147.76M | $136.37M | – | 40.2% | +27.0% |
| Germany | $89.46M | $85.19M | $79.41M | $75.51M | $72.21M | $68.23M | $65.26M | $62.50M | $60.19M | $60.84M | $60.21M | $55.30M | 12.8% | +23.9% |
| France | $84.14M | $81.21M | $76.19M | $71.63M | $67.25M | $63.10M | $55.73M | $47.58M | $36.49M | $22.22M | $11.74M | – | 12.0% | +25.1% |
| Other international markets | $65.87M | $60.64M | $56.90M | $51.04M | $46.65M | $45.44M | $42.47M | $40.33M | $36.91M | $33.88M | $32.76M | – | 9.4% | +41.2% |
| Japan | $41.62M | $39.32M | $37.79M | $36.09M | $35.28M | $33.46M | $32.57M | $31.61M | $30.62M | $30.82M | $31.67M | $32.01M | 6.0% | +18.0% |
| China | $20.98M | $19.62M | $19.44M | $16.78M | $15.81M | $17.07M | $17.39M | $19.81M | $21.94M | $22.85M | $23.22M | $23.69M | 3.0% | +32.7% |
| Others | – | – | – | – | – | – | – | – | – | – | – | $35.93M | – | – |
From the segment and revenue-disaggregation notes of NovoCure's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.